Clinical Trials
47 trialsNCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT07210775 2026-03-04
Topical Imiquimod Treatment of Oral Dysplasia
University of Southern California
Phase 1/2 Recruiting
NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
NCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT00314756 2023-08-22
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
Wake Forest University Health Sciences
Phase 4 Completed
NCT05740969 2023-02-23
PACKS
Zealand University Hospital
Phase 2 Unknown
NCT00142454 2022-10-10
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00189280 2022-02-22
Aldara for the Treatment of Large and/or Multiple sBCC
Viatris Inc.
Phase 3 Completed
NCT00189241 2022-02-07
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
Viatris Inc.
Phase 3 Completed
NCT00189267 2022-02-07
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
Viatris Inc.
Phase 2 Completed
NCT00294320 2022-02-07
Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
Viatris Inc.
Phase 3 Completed
NCT00777127 2022-02-07
LEIDA
Viatris Inc.
Phase 4 Completed
NCT01453179 2022-02-07
LEIDA 2
Viatris Inc.
Phase 4 Completed
NCT04842422 2022-01-11
Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
Medical University of Graz
Phase 4 Completed
NCT03914417 2021-01-20
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01686152 2020-11-24
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Teva Pharmaceuticals USA
Phase 3 Completed
NCT00948428 2020-09-04
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT04072900 2020-04-28
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
Phase 1 Unknown
NCT00118313 2020-03-27
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
Phase 1 Completed
NCT02120898 2019-12-13
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
Actavis Inc.
Phase 3 Completed
NCT01088737 2019-08-13
Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
Medical University of Graz
Phase 2/3 Unknown
NCT03116659 2019-08-13
CTCL Directed Therapy
James J. Peters Veterans Affairs Medical Center
Phase EARLY_PHASE1 Unknown
NCT01191034 2019-03-12
Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1/2 Terminated
NCT00814528 2018-09-10
Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses
University of Chicago
Phase NA Withdrawn
NCT02281682 2017-10-30
Akti
Maastricht University Medical Center
Phase 4 Unknown
NCT01538901 2017-09-12
AKtransplant
Medical University of Vienna
Phase 4 Terminated
NCT01264731 2016-12-16
MEL53
University of Virginia
Phase 1 Completed
NCT00774787 2016-11-07
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Rigel Dermatology
Phase 4 Completed
NCT00453050 2015-05-06
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
National Cancer Institute (NCI)
Phase 1 Completed
NCT01203878 2014-12-08
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Tennessee Clinical Research Center
Phase 4 Terminated
NCT00828568 2014-01-28
Bioequivalence Study of Two Imiquimod Cream 5%
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01788007 2014-01-22
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT00066872 2013-09-17
Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01611480 2013-06-26
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
Moberg Pharma AB
Phase 2 Completed
NCT00079300 2013-04-26
Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00581425 2013-01-25
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
The University of Texas Health Science Center, Houston
Phase 4 Completed
NCT00273910 2012-10-19
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00803907 2012-06-13
Imiquimod
University of Sao Paulo
Phase 4 Unknown
NCT00204555 2011-09-01
Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma
University Hospital Tuebingen
Phase 4 Completed
NCT01229319 2011-06-22
Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses
Frankel, Amylynne, M.D.
Phase 4 Unknown
NCT00651703 2010-11-15
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Cytos Biotechnology AG
Phase 2 Completed
NCT00335179 2010-07-23
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00116649 2010-07-20
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Graceway Pharmaceuticals, LLC
Phase 4 Completed
NCT00129519 2010-07-16
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
Graceway Pharmaceuticals, LLC
Phase 3 Completed
NCT00859105 2009-03-10
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis
Apotex Inc.
Phase 3 Completed
NCT00115154 2007-02-19
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
Graceway Pharmaceuticals, LLC
Phase 4 Completed
NCT00175643 2006-05-09
Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses
University of British Columbia
Phase 3 Completed